WilmerHale Advises Tetraphase Pharmaceuticals in Merger with AcelRx Pharmaceuticals
On March 16, 2020, Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, and AcelRx Pharmaceuticals (Nasdaq: ACRX) announced that they have entered into a definitive merger agreement pursuant to which AcelRx would acquire Tetraphase in a stock for stock transaction. Concurrently with signing the merger agreement, Tetraphase and AcelRx also entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain in medically supervised settings.
WilmerHale is representing Tetraphase in the deal, with a team led by partners
Stuart Falber,
Hal Leibowitz and
Chris Barnstable-Brown, which also included senior associate
Tim Kulis and associate
Meghan Fay on corporate and M&A matters, and partners
Kim Wethly,
Julie Hogan Rodgers,
Scott Kilgore and
Steve Barrett and associate
Ben Kelsey on tax, executive compensation, employment and benefits and intellectual property matters. Associate
Gerard Fischetti also worked on corporate and M&A matters.
Read the full press release.
